LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

47.567

105.69

Aktsiakasum

0.4

Dividenditootlus

0.31

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.81% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.31%

2.37%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

-815M

10B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

36%

64%

127 / 374 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 17:45 UTC

Tulu
Suurimad hinnamuutused turgudel

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. nov 2025, 17:31 UTC

Tulu
Suurimad hinnamuutused turgudel

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14. nov 2025, 16:15 UTC

Suurimad hinnamuutused turgudel

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14. nov 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. nov 2025, 22:35 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. nov 2025, 22:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. nov 2025, 22:29 UTC

Tulu

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. nov 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. nov 2025, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

14. nov 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. nov 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. nov 2025, 19:29 UTC

Market Talk
Tulu

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. nov 2025, 18:44 UTC

Market Talk
Tulu

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. nov 2025, 17:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

14. nov 2025, 17:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

14. nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. nov 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14. nov 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14. nov 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. nov 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

19.81% tõus

12 kuu keskmine prognoos

Keskmine 111.1 USD  19.81%

Kõrge 125 USD

Madal 100 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

8

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

127 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat